Complement Inhibitors - Myasthenia Gravis Treatment Market Statistics
The global complement inhibitors myasthenia gravis treatment market size was valued at US$ 1,047.4 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 2.5% from 2024 to 2045.
Related Statistics
Complement Inhibitors - Myasthenia Gravis Treatment Market Outlook highlights
- The global complement inhibitors segment generated a revenue of USD 1,047.4 million in 2024 and is expected to reach USD 2,050.7 million by 2045.
- The market is expected to grow at a CAGR (2025 - 2045) of 2.5% by 2045.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2045.
Market summary
| Market revenue in 2024 | USD 1,047.4 million |
| Market revenue in 2045 | USD 2,050.7 million |
| Growth rate | 2.5% (CAGR from 2025 to 2045) |
| Historical data covered | 2022 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2045 |
| Quantitative units | Revenue in USD million |
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia gravis treatment market segmentation & scope
Veopoz (Pozelimab)
Gefurulimab
Batoclimab
Other FcRn Inhibitors
Cell Therapies
CAR-T Cell Therapy
T-Cell Receptor Therapy
Anti-CD19 Monoclonal Antibodies (mAbs)
Myasthenia Gravis Treatment Market Outlook
- HTML
- PPT
- -
Everything on Myasthenia Gravis Treatment Market in one document: edited and divided into chapters, including detailed references.
Related industry reports
Related Regional Reports
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
